Andreas Zingg

Desialylation enhances bispecific T cell engager responses by relieving a sialoglycan-dependent restraint in human T cells.

This study shows that local glycan engineering using AAV-delivered sialidases reduces tumor growth and enhances systemic antitumor immunity through improved cross-presentation and dendritic cell activation.

This study profiles tumor-reactive T cell dynamics during TIL therapy in metastatic melanoma, identifying factors associated with response and resistance.

The paper identifies CD39+ tumor-associated NK cells as a cytotoxic effector state in NSCLC responsive to NKG2A blockade through multiomic analysis.

This study screens TCR-based CAR designs to improve anti-tumor efficacy by incorporating CD28 and CD27 costimulatory domains, showing enhanced performance in mouse tumor models.

This study develops a fully human CAR-T cell therapy targeting the STn antigen, showing activity in preclinical models of gastro-intestinal and gynecological cancers.

This study develops CAR T cells targeting a specific mutation in CLL to selectively kill cancer cells while sparing healthy B cells.